| abstract |
A novel and stable high purity torsemide variant II pharmaceutical preparation for oral administration is disclosed. This formulation releases high purity torsemide variant II at a constant rate and high purity in water, and the high purity torcemide variant II does not rearrange to torsemide variant I over time. Methods of making them are also disclosed. |